Portola Pharmaceuticals   Print Page    Close Window

Corporate Profile

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. Our first commercial product, Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor anticoagulant, is approved in the United States. We are also advancing the clinical development of two ot... Read More

Stock Quote
NASDAQ PTLA (Common Stock)
$53.22 - 1.48
Stock chart for: PTLA.O.  Currently trading at $53.22 with a 52 week high of $67.10 and a 52 week low of $15.68.
08/17/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Upcoming EventsMore >>
There are currently no events scheduled.
Archived Events
Q2 2017 Portola Pharmaceuticals, Inc. Earnings Conference Call
Wednesday, August 9, 2017 1:30 p.m. PT

Portola Pharmaceuticals Call on Bevyxxa (betrixaban) Approval
Friday, June 23, 2017 4:30 p.m. ET